Literature DB >> 22784350

Capacity for clinical research on herbal medicines in Africa.

Merlin Willcox1, Nandi Siegfried, Quinton Johnson.   

Abstract

An electronic survey was used to assess the training needs of clinical and public health researchers who have been involved, and/or plan to become involved, in clinical trials of herbal medicines in Africa. Over 90 researchers were contacted through pre-existing networks, of whom 58 (64%) responded, from 35 institutions in 14 African countries. Over half (57%) had already been involved in a clinical trial of an herbal medicine, and gave information about a total of 23 trials that have already been completed. Of these, only five had been published, and only one had resulted in a licensed product. Fifty-four (54) of the researchers were planning to conduct a clinical trial of an herbal medicine in the future, and gave information about 54 possible trials. Respondents outlined the following most commonly encountered difficulties when conducting clinical trials: resource constraints (including lack of funding, equipment, staff, and infrastructure); social acceptance of the clinical trial (including difficulty recruiting enough patients, poor rapport with traditional healers, and willingness of biomedical staff to be involved); herbal medicine supply (including insufficient cultivation, production, and quality control); lack of trained staff; and logistical issues in conducting trials. The topics in which researchers were least confident were Intellectual Property Rights issues, statistical issues, and issues related to Good Clinical Practice guidelines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22784350      PMCID: PMC3390968          DOI: 10.1089/acm.2011.0963

Source DB:  PubMed          Journal:  J Altern Complement Med        ISSN: 1075-5535            Impact factor:   2.579


  4 in total

1.  Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN in patients with Sickle Cell Disorder.

Authors:  C Wambebe; H Khamofu; J A Momoh; M Ekpeyong; B S Audu; O S Njoku; E A Bamgboye; R N Nasipuri; O O Kunle; J I Okogun; M N Enwerem; J G Audam; K S Gamaniel; O O Obodozie; B Samuel; G Fojule; O Ogunyale
Journal:  Phytomedicine       Date:  2001-07       Impact factor: 5.340

Review 2.  Traditional herbal medicines for malaria.

Authors:  Merlin L Willcox; Gerard Bodeker
Journal:  BMJ       Date:  2004-11-13

3.  Assessment of the short-term safety and tolerability of a quantified 80 % ethanol extract from the stem bark of Nauclea pobeguinii (PR 259 CT1) in healthy volunteers: a clinical phase I study.

Authors:  Kahunu Mesia; Kanyanga Cimanga; Lutete Tona; Ma Miezi Mampunza; Nsengi Ntamabyaliro; Tsobo Muanda; Tamfum Muyembe; Jozef Totté; Tony Mets; Luc Pieters; Arnold Vlietinck
Journal:  Planta Med       Date:  2010-07-21       Impact factor: 3.352

Review 4.  Do ethnobotanical and laboratory data predict clinical safety and efficacy of anti-malarial plants?

Authors:  Merlin Willcox; Françoise Benoit-Vical; Dennis Fowler; Geneviève Bourdy; Gemma Burford; Sergio Giani; Rocky Graziose; Peter Houghton; Milijaona Randrianarivelojosia; Philippe Rasoanaivo
Journal:  Malar J       Date:  2011-03-15       Impact factor: 2.979

  4 in total
  7 in total

Review 1.  Prunus africana (Hook.f.) Kalkman: the overexploitation of a medicinal plant species and its legal context.

Authors:  Gerard Bodeker; Charlotte van 't Klooster; Emma Weisbord
Journal:  J Altern Complement Med       Date:  2014-09-16       Impact factor: 2.579

2.  Research Capacity at Traditional Chinese Medicine (TCM) Centers in China: A Survey of Clinical Investigators.

Authors:  Shuo Feng; Mei Han; Lily Lai; Si-Cheng Wang; Jian-Ping Liu
Journal:  Evid Based Complement Alternat Med       Date:  2017-03-08       Impact factor: 2.629

3.  Capacity for ethical and regulatory review of herbal trials in developing countries: a case study of Moringa oleifera research in HIV-infected patients.

Authors:  Tsitsi G Monera-Penduka; Charles C Maponga; Gene D Morse; Charles F B Nhachi
Journal:  J Pharm Policy Pract       Date:  2017-02-20

Review 4.  Integration of botanicals in contemporary medicine: road blocks, checkpoints and go-ahead signals.

Authors:  Neha Arora Chugh; Shreya Bali; Ashwani Koul
Journal:  Integr Med Res       Date:  2018-03-28

5.  Short-Term Safety and Tolerability of an Antimalarial Herbal Medicine, CoBaT-Y017 in Healthy Volunteers.

Authors:  Adrien N Noudjiegbe; Adeline L Gnimassou; Judith S Gbenoudon; Jean-Eudes Degbelo; Aurel C E Allabi
Journal:  Evid Based Complement Alternat Med       Date:  2019-04-21       Impact factor: 2.629

6.  Lessons from the field: the conduct of randomized controlled trials in Botswana.

Authors:  Janice M Bonsu; Rosemary Frasso; Allison E Curry
Journal:  Trials       Date:  2017-10-27       Impact factor: 2.279

7.  A Phase II Pilot Trial to Evaluate CoBaT-Y017 Safety and Efficacy against Uncomplicated Falciparum Malaria versus Artemether-Lumefantrine in Benin Subjects.

Authors:  Adrien N Noudjiegbe; Femi N Alikekere; Henri Tchehouenou; Yéman Langa; Daniel S Ota; Jean-Eudes Degbelo; Aurel C E Allabi
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-17       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.